MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016

MARIETTA, Ga., Jan. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of...